Aditum Bio

Aditum Bio is a company focused on acquiring and developing pharmaceutical assets to enhance patient access to innovative medicines that may not be pursued by traditional developers. Established in 2019, Aditum Bio operates from its headquarters in San Francisco, California, and is dedicated to advancing the biotechnology and life sciences sectors. By identifying and nurturing promising pharmaceutical opportunities, Aditum Bio aims to bridge the gap between emerging therapies and patient needs, ultimately contributing to the improvement of healthcare outcomes.

Mark Fishman

Co-Founder and Chair of the Scientific Advisory BoardAditum Bio

Josh Gertsman

Principal

Andy Kadlec Ph.D

Principal

Praveena Kandula MD

Partner

5 past transactions

Tempero Bio

Series B in 2025
Tempero Bio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for treating and preventing substance use disorders. The company aims to address the challenges faced by individuals struggling with addiction, providing innovative treatments that facilitate recovery and improve overall health outcomes. By specializing in this critical area of healthcare, Tempero Bio seeks to make a meaningful impact on the lives of patients affected by substance use disorders and related conditions.

Hubpay

Series A in 2022
Hubpay is an independently regulated provider of cross-border money services aimed at enhancing financial inclusion in emerging markets. The company operates an online financial platform that facilitates overseas money transfers, offering services such as competitive foreign exchange, multi-currency accounts, and payment systems for suppliers, partners, and employees. By leveraging data science, Hubpay delivers accessible and affordable financial solutions, enabling users to conduct instant money transfers with ease. This allows businesses and individuals to manage their finances effectively, regardless of their income level, and concentrate on their growth without the stress of complex financial transactions.

Via Nova Therapeutics

Series A in 2021
Via Nova Therapeutics is a biopharmaceutical company focused on discovering and developing therapeutics for acute and subacute viral infections that lack effective treatments. The company’s portfolio includes antiviral programs targeting significant respiratory viruses such as influenza, adenoviruses, and rhinoviruses, as well as human polyomaviruses, which can cause severe illness in immunocompromised individuals. By concentrating on the fundamental mechanisms of viral replication, Via Nova Therapeutics aims to facilitate the development of novel therapeutics not only for its current targets but also for a broader range of viral infections.

Versanis Bio

Series A in 2021
Versanis Bio is a biopharmaceutical company focused on discovering and developing innovative medicines for medical conditions commonly affecting older adults. The company is advancing Bimagrumab, a human monoclonal antibody that targets activin type II receptors, effectively blocking ligands such as activin A and myostatin. Bimagrumab has undergone extensive clinical evaluation in over a dozen trials with more than 1,500 participants, demonstrating its ability to induce significant fat loss while preserving lean mass. Additionally, treatment with Bimagrumab has shown improvements in HbA1c levels and other cardiometabolic parameters, thereby assisting overweight and obese adults in achieving and maintaining a healthier body composition.

Anteris Bio

Acquisition in 2020
Anteris Bio is developing a new therapy for the treatment of renal disease.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.